NCT06220318 2025-11-28
Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors
Fujian Haixi Pharmaceuticals Co., Ltd.
Phase 1/2 Active not recruiting
Fujian Haixi Pharmaceuticals Co., Ltd.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Hutchmed
RemeGen Co., Ltd.
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co. Ltd.
Chinese PLA General Hospital
Beijing Friendship Hospital
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co. Ltd.
ChineseAMS
Innovent Biologics (Suzhou) Co. Ltd.